An Ottawa company that helps law enforcement agencies, hospitals and medical laboratories track samples of blood, saliva and other bodily fluids collected from patients and crime scenes has received a cash infusion from a U.S. health-tech firm to fund its southern expansion push.
STACS DNA said Tuesday that InVita Healthcare Technologies has acquired a majority stake in the company in a deal that closed earlier this month. Further financial details of the transaction were not disclosed.
STACS president and chief operating officer Jocelyn Tremblay said the new investment will give the bootstrapped 35-person firm the financial backing it needs to scale up in the U.S. market.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Ultragenyx Announces Approval of Dojolvi™ (UX007/triheptanoin) in Canada for the Treatment of .
Ultragenyx Pharmaceutical Inc.February 17, 2021 GMT
NOVATO, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that Health Canada has approved Dojolvi™ (triheptanoin) as a source of calories and fatty acids for the treatment of adult and pediatric patients with long-chain fatty acid oxidation disorders (LC-FAOD). Long-chain fatty acid oxidation disorders (LC-FAOD) are a group of rare, genetic, life-threatening disorders caused by defects in the enzymes needed to produce energy from fatty acids. Dojolvi is a highly purified, synthetic, 7-carbon fatty acid triglyceride specifically designed to pro